股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 先聲藥業集團有限公司 (於香港註冊成立的有限公司) 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 不適用 備註： 本公司乃於香港註冊成立。根據香港《公司條例》(第 622 章)，在香港註冊成立的公司沒有法定股本，因此並無"面值"的概念。 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02096 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 2,474,697,618 | | 0 | | 2,474,697,61 ...

先声药业 (02096. HK) 化学制药 买入 (维持) 评级: 分析师:穆奕杉 执业证书编号：S0740524070001 Email: muys@zts.com.cn 基本状况 分析师:祝嘉琦 执业证书编号：S0740519040001 Email: zhujq@zts.com.cn 分析师:曹泽运 执业证书编号: S0740524060002 Email: caozy01@zts.com.cn | 总股本(百万股) | 2,474.70 | | --- | --- | | 流通股本(百万股) | 2.474.70 | | 市价(港元) | 13.01 | | 市值(百万港元) | 32.195.82 | | 流通市值(百万港 | 32,195.82 | | 元) | | 股价与行业-市场走势对比 118% 750 相关报告 1、《创新转型成效显著,自研管线 国际化可预期》 2025-04-05 2、《神经+肿瘤+自免三栖,产品矩 阵升级+研发创佳绩》 2025-02-24 证券研究报告/公司点评报告 2025 年 09 月 03 日 | 公司盈利预测及估值 | | | | | | | --- | -- ...

Group 1 - The Hong Kong stock market's innovative pharmaceutical sector has shown a significant rebound this year, with a total refinancing amount reaching HKD 173.8 billion in the first half of the year, a year-on-year increase of 227%, surpassing the total for the entire year of 2024 [1] - More than 10 innovative pharmaceutical companies in the Hong Kong market have conducted placement financing, reflecting their ambition to target global markets and leverage differentiated innovation advantages [1] - As a leading pharmaceutical company with a strong pipeline of innovative drugs, including a significant COVID-19 treatment, the company has opted for placement financing to strengthen its position in the innovative drug sector [1] Group 2 - On September 2, the company announced a placement financing plan to issue 121 million shares, aiming to raise approximately HKD 15.535 billion [2] - The pricing of the placement shares at HKD 12.95 represents an 8.03% discount to the closing price on September 1, 2025, and a 6.67% discount to the average closing price over the previous five trading days, indicating a reasonable discount range typical in the Hong Kong market [5][6] - The placement is designed to meet significant financing needs while controlling the dilution effect on existing shareholders, reflecting management's consideration for shareholder interests [6] Group 3 - The introduction of long-term institutional investors is expected to optimize the company's shareholder structure and enhance corporate governance, laying the groundwork for potential overseas capital operations [7] - Following the announcement of the placement, the company's stock experienced short-term volatility but also saw a record trading volume of over 180 million shares on the same day, indicating strong market demand and recognition of long-term value [7][8] Group 4 - The company has transformed rapidly into an innovative pharmaceutical entity, with a reported revenue growth of 15.1% to HKD 3.585 billion and an adjusted net profit increase of 21.1% to HKD 651 million, driven primarily by its innovative drug business [8] - The company has launched ten innovative drugs, with revenue from these drugs reaching HKD 2.776 billion, a 26% increase, accounting for 77.4% of total revenue [8] - Approximately 90% of the funds raised from the placement will be allocated to research and development, focusing on core areas such as neurology, oncology, autoimmune diseases, and infections, which will further expand the company's global pipeline [9]

Core Viewpoint - The Hong Kong stock market's innovative pharmaceutical sector has shown a significant rebound this year, with a notable increase in refinancing activities, reflecting the ambition of domestic innovative drug companies to expand globally and leverage differentiated innovation advantages [1] Group 1: Financing Activities - The total refinancing amount in the Hong Kong market reached HKD 173.8 billion in the first half of the year, a year-on-year increase of 227%, surpassing the total for the entire year of 2024 [1] - More than 10 innovative pharmaceutical companies in the Hong Kong market have conducted placement financing, indicating a strong demand for capital to support research and development [1] - The company Xiansheng Pharmaceutical announced a placement financing plan to raise approximately HKD 1.5535 billion by issuing 121 million shares, reflecting its strategic move during a critical development phase [2][5] Group 2: Pricing and Market Response - The placement price of HKD 12.95 per share represents an approximately 8.03% discount to the closing price on September 1, 2025, and a 6.67% discount to the average closing price over the previous five trading days, which is within the common discount range of 5%-10% for stock issuances in the Hong Kong market [5][6] - The issuance of 121 million new shares will account for approximately 4.66% of the expanded total issued share capital, balancing the company's financing needs with shareholder interests [6] - Following the announcement, the stock price of Xiansheng Pharmaceutical experienced short-term fluctuations, but the trading volume exceeded 180 million shares, setting a new record since its listing, indicating strong market interest [7] Group 3: Company Performance and Strategy - Xiansheng Pharmaceutical has transformed into a leading innovative drug company, with a reported revenue growth of 15.1% to HKD 3.585 billion and an adjusted net profit increase of 21.1% to HKD 651 million, driven primarily by its innovative drug business [8] - The company has launched ten innovative drugs, with revenue from these drugs reaching HKD 2.776 billion, a 26% increase, accounting for 77.4% of total revenue [8] - Approximately 90% of the funds raised from the placement will be allocated to research and development, focusing on core areas such as neurology, oncology, autoimmune diseases, and anti-infection, which will enhance the company's global pipeline and validate its Biopharma value [9]

来源：第一财经 恒指跌0.11%，恒生科技指数跌0.11%。贵金属板块普涨，中国白银集团、中国黄金国际涨超3%；医药 股普遍回调，先声药业跌超6%。 ...

Core Viewpoint - The company, Xiansheng Pharmaceutical (2096.HK), experienced a significant drop in stock price, falling over 7% to HKD 13.04, following the announcement of a share placement to raise funds for research and operational needs [1] Group 1: Fundraising Details - The company announced a placement of 121 million shares, representing approximately 4.66% of the enlarged share capital [1] - The placement price is set at HKD 12.95 per share, which is an 8.03% discount compared to the closing price of HKD 14.08 from the previous day [1] - The total funds raised are expected to be HKD 15.67 billion [1] Group 2: Use of Proceeds - Approximately 90% of the net proceeds, amounting to HKD 15.54 billion, will be allocated for research and development expenses [1] - The funds will support clinical research for new drugs in both China and the United States, aiming to accelerate the development process [1] - The remaining 10% of the proceeds will be used for working capital and other general corporate purposes to sustain the company's daily operations and long-term development needs [1]

Group 1 - The company expects to raise approximately HKD 1.567 billion from the subscription, with a net amount of about HKD 1.554 billion [1] - 90% of the net proceeds will be allocated to research and development expenses, including accelerating clinical studies for new drugs in China and the United States, as well as supporting the expansion of new indications for approved innovative drugs [1] - The remaining 10% of the net proceeds will be used for working capital and general corporate purposes [1] Group 2 - Simcere Pharmaceutical Holding Limited and the company have entered into a placement and subscription agreement, with the seller selling 121 million shares at a price of HKD 12.95 per share, representing approximately 4.89% of the total shares issued as of the announcement date [3] - The company will issue an equal number of shares to the seller at the same subscription price of HKD 12.95 per share [3]

Core Viewpoint - The company, Sihuan Pharmaceutical Holdings Group Ltd (02096), has entered into a placement and subscription agreement to issue 121 million shares at a price of HKD 12.95 per share, aiming to raise approximately HKD 1.567 billion for research and operational needs [1] Group 1 - The seller, Simcere Pharmaceutical Holding Limited, plans to sell 121 million shares through the placement agent at a price of HKD 12.95 per share [1] - The total estimated proceeds from the subscription are approximately HKD 1.567 billion, with a net amount of about HKD 1.5535 billion [1] - Approximately 90% of the proceeds will be allocated for research and development expenses, while around 10% will be used for working capital and other general corporate purposes [1]

卖方(即Simcere Pharmaceutical Holding Limited)为一间根据开曼群岛法律于2014年8月15日注册成立的获 豁免有限公司，由最终控股股东间接控制。于本公告日期，卖方直接持有约9.38亿股股份，占公司已发 行股份总数约37.92%。 假设公司已发行股本自本公告日期起至认购完成并无变动(发行认购股份除外)，且假设所有认购股份已 获认购，销售股份占公司于本公告日期已发行股份总数约4.89%，及经配发及发行认购股份扩大的已发 行股份总数约4.66%。每股12.95港元的配售价较股份于最后交易日在联交所所报收市价每股股份14.08 港元折让约8.03%。 格隆汇9月2日丨先声药业(02096.HK)发布公告，2025年9月2日(交易时段前)，公司、卖方及配售代理(即 摩根士丹利)订立配售及认购协议，据此(i)卖方已有条件同意委任摩根士丹利亚洲有限公司担任配售代 理，以促使不少于六名买方按配售价(即每股12.95港元)购买(或倘未能促使彼等购买则自行购买)销售股 份(即1.21亿股股份)；及(ii)公司已有条件同意向卖方发行及卖方有条件同意以认购价(即每股12.95港 元，相当于配售价 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任 何損失承擔任何責任。 本公告或其任何副本概不得直接或間接在美國，或在刊發或派發本公告可能屬違法的任何其他司法管轄權 區內刊發或派發。 本公告僅供參考之用，並不構成收購、購買或認購本公司任何證券之邀請或要約。 本公告並不構成在美國購買或認購任何證券之要約或招攬，亦不構成其一部分。本公告所述證券並無且將 不會根據美國《 1933 年證券法（經修訂）》（「美國證券法」）或美國任何其他州證券法登記，及不得在美國提呈 發售或出售，除非根據美國證券法作出登記或獲豁免登記或為毋須根據美國證券法作出登記之交易。本公 司無意根據美國證券法登記本公告內所述之任何證券，或在美國進行證券之公開發售。本公告中所述的證 券並無亦不會於美國或該等發售受到限制或禁止的其他司法管轄區內進行公開發售。 Simcere Pharmaceutical Group Limited 先聲藥業集團有限公司 （於香港註冊成立的有限公司） （股份代號：2096） 配售現有股 ...